Envista Holdings Corporation — FY2021 Form 10-K
Reporting period: Year ended December 31, 2021. This is an annual filing, not a standalone Q4 report; selected Q4 results are noted below. Financial amounts are in U.S. dollars.
Business context
Envista sells dental implants, orthodontic products, imaging equipment, consumables and related software and services through two segments: Specialty Products & Technologies (S&T) and Equipment & Consumables (E&C). The company reported serving more than one million dentists in over 140 countries. FY2021 continuing-operations sales were $2.509 billion; consumables, services and spare parts represented approximately 82% of sales.
Financial performance
| Metric | FY2021 | FY2020 |
|---|---|---|
| Sales | $2,508.9 million | $1,929.1 million |
| Core sales growth (non-GAAP) | 29.0% | (15.0)% |
| Gross profit / margin | $1,426.5 million / 56.9% | $1,054.8 million / 54.7% |
| Operating profit / margin | $306.2 million / 12.2% | $43.5 million / 2.3% |
| Continuing-operations income | $263.5 million | $42.5 million |
| Net income, including discontinued operations | $340.5 million | $33.3 million |
| Operating cash flow | $361.6 million | $283.9 million |
| Capital expenditures | $54.7 million | $47.7 million |
- Sales rose 30.1% year over year; reported growth included a 1.5% negative foreign-exchange impact and a 0.4% benefit from discontinued products. Management attributed the rebound primarily to higher volume and improved product mix as dental practices reopened and patient demand recovered.
- S&T sales were $1,507.8 million, up 34.9%; segment operating profit was $272.3 million, or 18.1% of sales (versus 5.9% in 2020). E&C sales were $1,001.1 million, up 23.3%; segment operating profit was $153.8 million, or 15.4% (versus 6.6%).
- FY2021 diluted EPS was $1.48 from continuing operations and $1.92 including discontinued operations. The effective tax rate was negative 3.5%, primarily reflecting Swiss deferred-tax benefits and valuation-allowance releases; it is not a straightforward indicator of a recurring tax rate.
- Q4 2021 sales were $651.8 million and continuing-operations income was $42.5 million, compared with $616.3 million and $91.1 million, respectively, in Q4 2020. Q4 diluted EPS from continuing operations was $0.24 versus $0.54.
Liquidity, debt and balance sheet
- At December 31, 2021, cash and cash equivalents were $1,073.6 million, including $594.2 million held outside the United States. Total debt carrying value was $1,315.8 million: $432.4 million classified current and $883.4 million long term. The company reported no revolver borrowings and $750 million of revolving capacity; it was in compliance with debt covenants.
- Debt included $517.5 million principal of 2.375% convertible notes due 2025. Because a stock-price conversion condition was met, the notes were classified as current at year-end. Their reported carrying value was $432.1 million, while fair value was $1,162.5 million.
- Operating cash flow increased by $77.7 million from 2020. Investing cash flow was $262.7 million provided, including $312.5 million of cash proceeds from the KaVo divestiture. Financing cash flow was $465.6 million used, primarily reflecting repayment of $472.0 million of the Euro Term Loan.
- Management said available liquidity was sufficient for expected needs over the next 12 months and beyond. The filing provides no specific earnings or revenue guidance.
Material changes, outlook and risks
- Portfolio changes: Envista completed the sale of its KaVo Treatment Unit and Instrument Business on December 31, 2021. It received $317.3 million at closing and expected a $30 million earnout and approximately $40.9 million of purchase-price adjustments in 2022, subject to terms and adjustments. The business was presented as discontinued operations; FY2021 discontinued-operations income was $77.0 million, including an $11.7 million after-tax sale gain.
- Pending acquisition: Envista agreed to acquire Carestream’s intraoral scanner business for $600 million, subject to customary adjustments, with an expected Q2 2022 close. Completion, integration, financing and realization of expected benefits were uncertain.
- COVID-19 and supply chain: Dental practices had largely reopened, but patient volumes remained below pre-pandemic levels. Management cited pandemic variants, labor and raw-material shortages, and higher prices for certain chemicals and microchips as ongoing uncertainties.
- Costs and restructuring: FY2021 restructuring charges were $63.6 million, with $29.8 million of non-cash impairment and inventory write-offs related to facility consolidation. Management’s strategy emphasizes cost efficiency and reinvestment in implants, orthodontics, digital workflows and emerging markets.
- Other exposures: Key risks include customer/distributor concentration (Henry Schein represented 12% of sales), competition, regulation of medical devices, cybersecurity and data privacy, foreign exchange, acquisition execution, litigation and leverage. Accrued legal contingencies were $38.7 million; management did not expect the ultimate outcome, net of accruals, to materially affect financial position, while acknowledging period-specific effects could be material.
- Auditors issued unqualified opinions on the financial statements and internal control over financial reporting. Goodwill was $3.132 billion; no goodwill impairment was recorded in 2021.
Investor verification priorities
- Assess the Q4 decline in continuing-operations income despite higher year-over-year sales, and distinguish quarterly from full-year trends.
- Review the composition and repeatability of the tax benefits behind the negative FY2021 effective tax rate and reported earnings.
- Verify cash proceeds, deferred local closings, earnout and adjustments from the KaVo divestiture, and the resulting continuing-operations revenue base.
- Evaluate funding and covenant capacity for the $600 million scanner acquisition alongside debt maturities and the convertible notes’ current classification and potential dilution/cash settlement.
- Monitor whether patient volumes, supply availability and costs, restructuring savings, and growth investments support continued margin improvement.